Russia's Sputnik V could be made in European Union after reported deals
MOSCOW (Reuters) – Russia’s Sputnik V vaccine against COVID-19 could be produced in western Europe for the first time after a deal to make it in Italy was signed by the RDIF sovereign wealth fund and Swiss-based pharmaceutical company Adienne.
The agreement, which will need approval from Italian regulators before production can be launched, has been confirmed by both Russia’s RDIF, which markets Sputnik V internationally, and the Italian-Russian chamber of commerce.
Kirill Dmitriev, RDIF’s head, told Russian state TV his fund had also struck deals with production facilities in Spain, France and Germany to produce Sputnik. He did not provide details.
It is the latest indication that some companies are not willing to wait for the European Union’s (EU’s) regulator — the European Medicines Agency (EMA) — to grant its approval to Sputnik V before pushing ahead with their own plans.
Scientists said the Russian vaccine was almost 92% effective, based on peer-reviewed late-stage trial results published in The Lancet medical journal last month.
Sputnik V has already been approved or is being assessed for approval in three EU member states – Hungary, Slovakia and the Czech Republic. EU officials have said Brussels could start negotiations about a possible agreement to buy vaccines if at least four members request it.
European Council President Charles Michel on Tuesday took aim at what he called “highly publicised” supply of vaccines from China and Russia to other countries, calling on EU members not to be misled.
ITALIAN BREAKTHROUGH?
The Italian-Russian chamber of commerce said on Monday that the Italian move paved the way for the creation of the first Sputnik V production facility in Europe outside Russia.
It said there were plans for Italian production to begin in June and that it hoped that 10 million doses of Sputnik V could be produced there by the end of the year.
“This agreement is the first of its kind with a European partner,” Vincenzo Trani, head of the chamber, said in the statement. “It can be called a historic event, which is proof of the good state of relations between our countries and shows that Italian companies can see beyond political differences.”
The Lugano-based Adienne Pharma & Biotech did not immediately respond to a request for comment. RDIF declined to provide further detail on the deal beyond confirming it.
Kremlin spokesman Dmitry Peskov said the Italy-related plan could help quickly satisfy demand for the shot abroad.
An EMA official urged EU members last week to refrain from approving Sputnik V at the national level while the agency was still reviewing it, prompting the vaccine’s developers to demand a public apology.
Peskov called the EMA official’s comment “inappropriate at the very least”.
A spokesman for Italian Prime Minister Mario Draghi said Rome was not applying particular pressure on the EU to secure the approval of Sputnik V. He said Draghi had urged the bloc to pursue all possible options to secure vaccines approved by the EMA.
Source: Read Full Article